Do you have the same question? Follow this Question
Aug 14, 2025 - 12:11 PM
We’ve provided several answers to questions related to Brukinsa (Zanubrutinib) , see some other helpful Q&A related to this product.
Question: What is the impact of this medicine on neutrophil, platelet, and red blood cell levels?
Answer: The medicine may cause dangerously low levels of neutrophils, platelets, and red blood cells, requiring regular blood tests and possible adjustments in treatment. Monitoring blood counts helps in managing and mitigating the risks of low blood cell levels.
Question: Can this medicine cause infections?
Answer: Yes, the medicine can lead to serious infections, including pneumonia, and in some cases, these infections can be fatal. This risk emphasizes the need for vigilance and prompt reporting of infection symptoms to healthcare providers.
Question: What is the protein binding percentage of the medicine?
Answer: The protein binding percentage is 94%. High protein binding can affect the drug's distribution and duration of action, which is crucial for understanding how the medicine will interact within the body.
Question: What is the bioavailability of the medicine?
Answer: The bioavailability of the medicine ranges from approximately 15% to 30%. Bioavailability indicates the extent and rate at which the active ingredient is absorbed and becomes available at the site of action, which is important for understanding its effectiveness.
